ARCHIVES

Adverse data from cancer prevention trial makes Merck withdraw Vioxx from market. Researchers discuss implications for other cancer prevention trials.

This article is from The Cancer Letter archive.

Vol. 30 No. 39 | October 15, 2004

Download PDF Visit The Full Archive

Related Articles

DeVita Seeks End to Funding For CROS, Reacts With Anger To Charge Of “Central Direction From Washington”

February 20, 1981

Possible Breach of Patient Confidentially By Calif. Physician; NCI

May 6, 1994

CCIRC Fears Multimodality Studies Threatened By Cooperative Groups’ Misapplication Of Funds

January 14, 1977

In Brief: New Mount Sinai Cancer Center Gets $7 Million; Jules Harris Named Rush Cancer Center Director

July 25, 1986

Feinstein Slams Cancer Act Proposal, Calls White Paper Vague And Unrealistic.

October 19, 2001

Bush Increase For NIH In Sharp Contrast To Cuts In Health Delivery Programs.

April 6, 2001